JACKSONVILLE, Fla., Oct. 12, 2017 /PRNewswire/
-- TapImmune Inc. (NASDAQ: TPIV), a leading
clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that
representatives of the Company will be featured in two panel discussions at the 2017 BioFlorida Conference, held October
15-17, at The Vinoy Renaissance St. Petersburg Resort and Golf Club. The Company will be featured in the BioBusiness
Session on Monday, October 16 th, and in the BioTrends Session on Tuesday, October 17 th, and will participate in one-on-one meetings with potential strategic
collaboration partners.
About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer. The Company is a leader in
the development of immunotherapies for women's cancers, with multiple Phase 2 and Phase 1b/2 clinical studies for the treatment
of ovarian and breast cancer. The company's peptide- or nucleic acid-based immunotherapeutic products comprise one or multiple
naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to
restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's
technologies may be used as stand-alone medications or in combination with current treatment modalities.
About BioFlorida
BioFlorida is the voice of Florida's life sciences industry, representing nearly
6,000 establishments and research organizations in the biopharmaceutical, medical technology and bioagriculture sectors that
collectively employ nearly 83,000 Floridians.
For additional information, please call (904) 862-6490 EXT. 102 or visit: https://tapimmune.com/
To receive future press releases via email, please visit:
https://tapimmune.com/investors/email-alerts/
Follow us on Twitter @Tapimmune_Inc, or follow
us on Facebook.
For answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act
of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance,
and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other
matters, are "forward-looking statements." Forward-looking statements are by their nature subject to risks, uncertainties and
other factors which could cause actual results to differ materially from those stored in such statements. Such risks,
uncertainties and factors include, but are not limited to the results of the Phase II clinical trials, the ability to obtain
regulatory approval of TPIV 200, the Company's ability to raise future financing for continued development and the ability to
successfully commercialize TPIV 200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q
and other SEC filings which are available through EDGAR at www.sec.gov. The
Company assumes no obligation to update the forward-looking statements.
View original content with multimedia:http://www.prnewswire.com/news-releases/tapimmune-to-present-at-the-2017-bioflorida-conference-300535062.html
SOURCE TapImmune Inc.